Biomarkers and algorithms for diagnosis of ovarian cancer: CA125, HE4, RMI and ROMA, a review
Published 2019 View Full Article
- Home
- Publications
- Publication Search
- Publication Details
Title
Biomarkers and algorithms for diagnosis of ovarian cancer: CA125, HE4, RMI and ROMA, a review
Authors
Keywords
HE4, CA125, ROMA, RMI, Ovarian cancer
Journal
Journal of Ovarian Research
Volume 12, Issue 1, Pages -
Publisher
Springer Nature
Online
2019-03-28
DOI
10.1186/s13048-019-0503-7
References
Ask authors/readers for more resources
Related references
Note: Only part of the references are listed.- The role of biomarkers in the management of epithelial ovarian cancer
- (2017) Wei-Lei Yang et al. EXPERT REVIEW OF MOLECULAR DIAGNOSTICS
- Combining a symptom index, CA125 and HE4 (triple screen) to detect ovarian cancer in women with a pelvic mass
- (2017) Barbara A. Goff et al. GYNECOLOGIC ONCOLOGY
- Correlates of circulating ovarian cancer early detection markers and their contribution to discrimination of early detection models: results from the EPIC cohort
- (2017) Renée T. Fortner et al. Journal of Ovarian Research
- Diagnostic accuracy of cancer antigen 125 for endometriosis: a systematic review and meta-analysis
- (2016) M Hirsch et al. BJOG-AN INTERNATIONAL JOURNAL OF OBSTETRICS AND GYNAECOLOGY
- Subjective assessment versus ultrasound models to diagnose ovarian cancer: A systematic review and meta-analysis
- (2016) E.M.J. Meys et al. EUROPEAN JOURNAL OF CANCER
- Is the Risk of Ovarian Malignancy Algorithm Better Than Other Tests for Predicting Ovarian Malignancy in Women with Pelvic Masses?
- (2016) Marut Yanaranop et al. GYNECOLOGIC AND OBSTETRIC INVESTIGATION
- CA125 and HE4: Measurement Tools for Ovarian Cancer
- (2016) Tingting Zhao et al. GYNECOLOGIC AND OBSTETRIC INVESTIGATION
- HE4, CA125 and risk of ovarian malignancy algorithm (ROMA) as diagnostic tools for ovarian cancer in patients with a pelvic mass: An Italian multicenter study
- (2016) Cesare Romagnolo et al. GYNECOLOGIC ONCOLOGY
- Improved Detection Rate of Ovarian Cancer Using a 2-Step Triage Model of the Risk of Malignancy Index and Expert Sonography in an Outpatient Screening Setting
- (2016) Gwendolin Manegold-Brauer et al. INTERNATIONAL JOURNAL OF GYNECOLOGICAL CANCER
- Performance of the Risk of Malignancy Index for Discriminating Malignant Tumors in Women With Adnexal Masses
- (2016) Camila Campos et al. JOURNAL OF ULTRASOUND IN MEDICINE
- Can ROMA algorithm stratify ovarian tumor patients better when being based on specific age ranges instead of the premenopausal and postmenopausal status?
- (2016) Anita Chudecka-Głaz et al. TUMOR BIOLOGY
- Body mass index does not influence human epididymis protein 4 concentrations in serum
- (2015) Simona Ferraro et al. CLINICA CHIMICA ACTA
- Human epididymis protein 4: Factors of variation
- (2015) Simona Ferraro et al. CLINICA CHIMICA ACTA
- A novel diagnostic index combining HE4, CA125 and age may improve triage of women with suspected ovarian cancer — An international multicenter study in women with an ovarian mass
- (2015) Mona A. Karlsen et al. GYNECOLOGIC ONCOLOGY
- Distinguishing benign from malignant pelvic mass utilizing an algorithm with HE4, menopausal status, and ultrasound findings
- (2015) Sarikapan Wilailak et al. Journal of Gynecologic Oncology
- The new FIGO staging system for ovarian, fallopian tube, and primary peritoneal cancer
- (2014) F. Zeppernick et al. ARCHIVES OF GYNECOLOGY AND OBSTETRICS
- Prognostic Value of Serum HE4 Levels and Risk of Ovarian Malignancy Algorithm Scores at the Time of Ovarian Cancer Diagnosis
- (2014) Jeroen Kaijser et al. INTERNATIONAL JOURNAL OF GYNECOLOGICAL CANCER
- Diagnostic accuracy of serum HE4, CA125 and ROMA in patients with ovarian cancer: a meta-analysis
- (2014) Jiwen Wang et al. TUMOR BIOLOGY
- Marqueurs sériques et tumoraux ovariens dans le diagnostic des tumeurs ovariennes présumées bénignes
- (2013) N. Lahlou et al. JOURNAL DE GYNECOLOGIE OBSTETRIQUE ET BIOLOGIE DE LA REPRODUCTION
- Recommandations pour la pratique clinique : tumeurs ovariennes présumées bénignes – Objectifs, méthodes et organisation
- (2013) J.-L. Brun et al. JOURNAL DE GYNECOLOGIE OBSTETRIQUE ET BIOLOGIE DE LA REPRODUCTION
- Serum human epididymis protein 4 vs carbohydrate antigen 125 for ovarian cancer diagnosis: a systematic review
- (2013) Simona Ferraro et al. JOURNAL OF CLINICAL PATHOLOGY
- The use of HE4, CA125 and CA72-4 biomarkers for differential diagnosis between ovarian endometrioma and epithelial ovarian cancer
- (2013) Emanuela Anastasi et al. Journal of Ovarian Research
- Is serum human epididymis protein 4 ready for prime time?
- (2013) Simona Ferraro et al. ANNALS OF CLINICAL BIOCHEMISTRY
- Does risk for ovarian malignancy algorithm excel human epididymis protein 4 and ca125 in predicting epithelial ovarian cancer: A meta-analysis
- (2012) Fake Li et al. BMC CANCER
- Interpretation of Single and Serial Measures of HE4 and CA125 in Asymptomatic Women at High Risk for Ovarian Cancer
- (2012) N. Urban et al. CANCER EPIDEMIOLOGY BIOMARKERS & PREVENTION
- A comparison of CA125, HE4, risk ovarian malignancy algorithm (ROMA), and risk malignancy index (RMI) for the classification of ovarian masses
- (2012) C Anton et al. Clinics
- Subjective assessment by ultrasound is superior to the risk of malignancy index (RMI) or the risk of ovarian malignancy algorithm (ROMA) in discriminating benign from malignant adnexal masses
- (2012) Toon Van Gorp et al. EUROPEAN JOURNAL OF CANCER
- Comparison of HE4, CA125 and ROMA algorithm in women with a pelvic mass: Correlation with pathological outcome
- (2012) M.T. Sandri et al. GYNECOLOGIC ONCOLOGY
- Human epididymis protein 4 offers superior specificity in the differentiation of benign and malignant adnexal masses in premenopausal women
- (2011) Kevin Holcomb et al. AMERICAN JOURNAL OF OBSTETRICS AND GYNECOLOGY
- Serum levels of the ovarian cancer biomarker HE4 are decreased in pregnancy and increase with age
- (2011) Richard G. Moore et al. AMERICAN JOURNAL OF OBSTETRICS AND GYNECOLOGY
- External Validation of Diagnostic Models to Estimate the Risk of Malignancy in Adnexal Masses
- (2011) C. Van Holsbeke et al. CLINICAL CANCER RESEARCH
- Potential Role of HE4 in Multimodal Screening for Epithelial Ovarian Cancer
- (2011) N. Urban et al. JNCI-Journal of the National Cancer Institute
- Human epididymis protein 4 reference limits and natural variation in a Nordic reference population
- (2011) Nils Bolstad et al. TUMOR BIOLOGY
- Serum biomarker panels for the discrimination of benign from malignant cases in patients with an adnexal mass
- (2010) Brian Nolen et al. GYNECOLOGIC ONCOLOGY
- Serum HE4 concentration differentiates malignant ovarian tumours from ovarian endometriotic cysts
- (2009) K Huhtinen et al. BRITISH JOURNAL OF CANCER
- Use of a Symptom Index, CA125, and HE4 to predict ovarian cancer
- (2009) M. Robyn Andersen et al. GYNECOLOGIC ONCOLOGY
- Cancer Statistics, 2008
- (2008) A. Jemal et al. CA-A CANCER JOURNAL FOR CLINICIANS
- Effects of Personal Characteristics on Serum CA125, Mesothelin, and HE4 Levels in Healthy Postmenopausal Women at High-Risk for Ovarian Cancer
- (2008) K. A. Lowe et al. CANCER EPIDEMIOLOGY BIOMARKERS & PREVENTION
- Do clear cell ovarian carcinomas have poorer prognosis compared to other epithelial cell types? A study of 1411 clear cell ovarian cancers
- (2008) John K. Chan et al. GYNECOLOGIC ONCOLOGY
- A novel multiple marker bioassay utilizing HE4 and CA125 for the prediction of ovarian cancer in patients with a pelvic mass
- (2008) Richard G. Moore et al. GYNECOLOGIC ONCOLOGY
- Preoperative evaluation and triage of women with suspicious adnexal masses using risk of malignancy index
- (2008) Christopher A. Enakpene et al. JOURNAL OF OBSTETRICS AND GYNAECOLOGY RESEARCH
- The use of multiple novel tumor biomarkers for the detection of ovarian carcinoma in patients with a pelvic mass
- (2007) Richard G. Moore et al. GYNECOLOGIC ONCOLOGY
Discover Peeref hubs
Discuss science. Find collaborators. Network.
Join a conversationPublish scientific posters with Peeref
Peeref publishes scientific posters from all research disciplines. Our Diamond Open Access policy means free access to content and no publication fees for authors.
Learn More